A Phase III Open-label Safety and Immunogenicity Study of GARDASIL 9 Administered to 9- to 26-Year-Old Females and Males in Vietnam
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2019
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 11 Feb 2019 Status changed from active, no longer recruiting to completed.
- 03 Aug 2018 Planned End Date changed from 19 Jul 2019 to 31 Jan 2019.
- 03 Aug 2018 Planned primary completion date changed from 19 Jul 2019 to 31 Jan 2019.